

Ambry Genetics® Gene-Disease Validity Scheme

The Ambry Classifi™ program is the way we actualize our promise to provide genetic test results of unparalleled quality. A cornerstone of the Classifi program is the Ambry Genetics Gene-Disease Validity Scheme, which is a points-based framework that allows for a clear understanding of gene disease characterization. Ambry is dedicated to routinely updating our Gene-Disease Validity Scheme to reflect published recommendations and scientific data to drive accurate gene associations to deliver high-confidence variant classifications.

Classification Score					
Disputed <0 points	No Evidence 0 points	Limited >0 to 7 points	Moderate 8 to 12 points	Strong 13 to 16 points	Definitive ≥17 points
	Point Range	Criteria			
GENETIC	1.00 to 18.00	Case-Control Studies (significant disease association)			
	0.1 to 18.00	Case-Level Data (Proband count weighted by <i>de novo</i> , functional, and segregation evidence)			
	3.00 to 7.00	Cohort Studies (significant enrichment)			
	0.5 to 1.00	Protein Regional Evidence (Missense constraint, hotspot, recurrent <i>de novo</i>)			
	0.1 to 3.00	Publication Count (with case-level data)			
EXPERIMENTAL	1.00 to 2.00	Gene Function (function, expression, interaction)			
	1.00 to 2.00	Gene Disruption (relevant altered protein function in appropriate assay(s))			
	1.00 to 2.00	Model Organism (relevant phenotype with appropriate genotype)			
GENETIC	-18.00 to -1.00	Case-Control Studies (demonstrated insignificant disease association)			

The Gene-Disease Validity Scheme is not intended for the interpretation of epigenetic factors including genetic modifiers, multifactorial disease, or low-risk disease association alleles and may be limited in the interpretation of diseases confounded by incomplete penetrance, variable expressivity, phenocopies, triallelic or oligogenic inheritance.